For patients with other cancer types, anti-PD-1/PD-L1 monotherapy was associated with increased tumor response in patients with PD-L1 expression ≥1% (RR 2.62 [1.47-4.68]; P = 0.001, Figure S5A) but not in those with PD-L1 expression <1% (RR 0.95 [0.30-2.97]; P = 0.930, Figure S5A). Here, PDCD1 is linked to cancer.